Selected article for: "Neutralization assay and plaque reduction neutralization"

Author: Funaro, Ada; Gribaudo, Giorgio; Luganini, Anna; Ortolan, Erika; Lo Buono, Nicola; Vicenzi, Elisa; Cassetta, Luca; Landolfo, Santo; Buick, Richard; Falciola, Luca; Murphy, Marianne; Garotta, Gianni; Malavasi, Fabio
Title: Generation of potent neutralizing human monoclonal antibodies against cytomegalovirus infection from immune B cells
  • Document date: 2008_11_12
  • ID: 1u2fkwx3_17
    Snippet: Clone stability was tested by maintaining the cells for 3 months in serum-free medium without CpG2006 or other additives, and the mAbs recovered in the supernatant at a concentration of 20-50 μg/ml. All purified IgG maintained their neutralizing activity; mAb 26A1 demonstrated a potent neutralizing capacity, with a calculated inhibitory concentration 50 (IC 50 ) of 0.92 μg/ml against AD169 in HELF (Fig. 3A) , and of 1 μg/ml against VR1814 in .....
    Document: Clone stability was tested by maintaining the cells for 3 months in serum-free medium without CpG2006 or other additives, and the mAbs recovered in the supernatant at a concentration of 20-50 μg/ml. All purified IgG maintained their neutralizing activity; mAb 26A1 demonstrated a potent neutralizing capacity, with a calculated inhibitory concentration 50 (IC 50 ) of 0.92 μg/ml against AD169 in HELF (Fig. 3A) , and of 1 μg/ml against VR1814 in HUVEC (Fig. 3B) . The potency of 26A1 against both HCMV strains was ~20 fold higher than the reference anti-HCMV IgG (IC 50 of 16 μg/ ml), currently used in transplant recipients. The inhibitory activity of mAb 26A1 against the whole viral replicative cycle was confirmed by plaque reduction neutralization assay ( Figure 3C ). The mechanism of virus neutralization is subject of ongoing studies.

    Search related documents:
    Co phrase search for related documents
    • Clone stability and neutralizing activity: 1
    • HCMV strain and inhibitory activity: 1
    • HCMV strain and inhibitory concentration: 1
    • HCMV strain and neutralizing activity: 1, 2, 3
    • inhibitory activity and neutralizing activity: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • inhibitory activity and plaque reduction neutralization: 1
    • inhibitory activity and reduction neutralization: 1
    • inhibitory concentration and neutralizing activity: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • inhibitory concentration and plaque reduction neutralization: 1
    • inhibitory concentration and plaque reduction neutralization assay: 1
    • inhibitory concentration and reduction neutralization: 1, 2
    • neutralizing activity and plaque reduction neutralization: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • neutralizing activity and plaque reduction neutralization assay: 1, 2, 3, 4, 5, 6
    • neutralizing activity and reduction neutralization: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • neutralizing capacity and ongoing study: 1
    • neutralizing capacity and plaque reduction neutralization: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • neutralizing capacity and plaque reduction neutralization assay: 1
    • neutralizing capacity and potent neutralizing capacity: 1, 2
    • neutralizing capacity and reduction neutralization: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10